Please use this identifier to cite or link to this item:
Title: Long-term effects of neridronate on human osteoblastic cell cultures
Authors: Frediani, Bruno
Spreafico, Adriano
Capperucci, Caterina
Chellini, Francesca
Gambera, Dario
Ferrata, Paolo
Baldi, Fabio
Falsetti, Paolo
Santucci, Annalisa 
Bocchi, Luigi
Marcolongo, Roberto
Keywords: Bisphosphonates; Bone markers; Neridronate; Osteoblasts; Osteoporosis treatment; Aged; Alkaline Phosphatase; Calcification, Physiologic; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen Type I; Diphosphonates; Female; Humans; Male; Middle Aged; Osteoblasts; RNA, Messenger; Time Factors; Physiology; Hematology
Issue Date: 2004
Project: None 
Journal: BONE
Bisphosphonates (BP's) are widely used in the treatment of a variety of bone-related diseases, particularly where the bone turnover is skewed in favor of osteolysis. The mechanisms by which BP's reduce bone resorption directly acting oil osteoclasts are now largely clarified even at molecular level. Researches concerning the BP's effects on osteoblast have instead shown variable results. Many in vitro studies have reported positive effects on osteoblasts proliferation and mineralization for several BPs, however, the observed effects differ, depending on the variety of different model system that has been used. Objectives. We have investigated if neridronate, an aminobisphosphonate suitable for pulsatory parenteral administration, could have an effect on human osteoblastic proliferation and differentiation in vitro. Methods. We have investigated whether prolonged addition of neridronate (from 10(-3) to 10(-11) M) to different human osteoblasts cultures, obtained from 14 different bone specimens, could affect the cells number, the endogenous cellular alkaline phosphatase (ALKP) activity, and the formation of mineralized nodules. Results. Our results show that neridronate does not negatively affect in vitro the viability, proliferation, and cellular activity of normal human osteoblasts even after a long period addition of the drug (20 days) at concentrations equal or lower than 10(-5) mol/l (therapeutic dose). In addition, neridronate seems to enhance the differentiation of cultured osteoblasts in mature bone-forming cells. A maximum increase of alkaline phosphatase activity (+50% after 10 days; P < 0.01) and mineralized nodules (+48% after 20 days; P < 0.05) was observed in cultures treated with neridronate 10(-8) M. Conclusions. These results encourage the use of neridronate in long-term therapy of demineralizing metabolic bone disorders.
ISSN: 8756-3282
DOI: 10.1016/j.bone.2004.06.001
Appears in Collections:Publications

Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.